4640 SW Macadam Avenue
About AbSciAbSci is a global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry. AbSci’s technology enables dramatic reductions in the cost of producing novel and existing biologics, acceleration of drug discovery timelines, and increased efficiency and flexibility throughout the manufacturing process.
Founders: Mark Valasek and Phil Barish
CEO: Sean McClain
Please click here for AbSci job opportunitites.
12 articles with AbSci
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
AbSci Develops Game-Changing 12-Week Cell Line Optimization Workflow and Adds Two New Members to Its Executive Team
Martina Molsbergen, Vice President, Business Development and Johan Kers, PhD, Vice President, Research.
AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi.
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. "AGC" includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.
AbSci, announced the addition of Coherus' CSO, Alan Herman, PhD to its Scientific Advisory Board.
A pioneer of the biotech industry, Dr. Bennett brings his decades of experience in downstream process development, protein purification, and regulatory affairs to the AbSci team.
Prior to formally joining AbSci's Scientific Advisory Board, Dr. Larimore advised AbSci on various aspects of biopharmaceutical process development manufacturing scale-up.